TPOXX® (tecovirimat)

Search documents
SIGA to Host Business Update Call on May 8, 2025 Following Release of First-Quarter 2025 Results
Globenewswire· 2025-05-01 11:30
Company Overview - SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on developing innovative medicines to treat and prevent infectious diseases, particularly orthopoxviruses [4] - The company aims to protect against severe infectious diseases through partnerships with governments and public health agencies [4] - SIGA's flagship product, TPOXX® (tecovirimat), is approved in the U.S. and Canada for smallpox treatment and authorized in Europe, the UK, and Japan for smallpox, mpox, cowpox, and vaccinia complications [4] Upcoming Events - Management will host a webcast and conference call for a business update on May 8, 2025, at 4:30 P.M. ET, featuring CEO Diem Nguyen and CFO Daniel Luckshire [1] - A live webcast will be accessible on the company's website in the Investor Relations section [2] - A replay of the call will be available for two weeks after the event, with specific dialing instructions provided for domestic and international callers [3]
SIGA Appoints Retired General John M. Keane to its Board of Directors
Newsfilter· 2025-03-18 11:30
Core Viewpoint - SIGA Technologies, Inc. has appointed Retired United States Army General John "Jack" Keane to its Board of Directors, which is expected to enhance the company's strategic capabilities in national security and biodefense [1][4]. Company Overview - SIGA Technologies is a commercial-stage pharmaceutical company focused on developing innovative medicines to treat and prevent infectious diseases, particularly orthopoxviruses [5]. - The company's flagship product, TPOXX® (tecovirimat), is FDA-approved for the treatment of smallpox and authorized in several countries for related diseases [5]. Appointment of General Keane - General Keane brings 37 years of public service experience, including roles as acting Chief of Staff and Vice Chief of Staff of the U.S. Army, and is recognized as a national security expert [2][3]. - His insights into global security challenges are expected to be invaluable for SIGA as it aims to expand its antiviral reach and collaborate with government stakeholders [4]. Strategic Alignment - General Keane expressed his commitment to SIGA's mission, emphasizing the importance of preparedness in national security and the company's role in supplying TPOXX to the U.S. strategic national stockpile [4].